Gonadorelin

What Gonadorelin does

Gonadorelin copies a brain signal for ovulation and sperm production; fertility studies mainly use frequent pump pulses. Twice-weekly shots alongside testosterone therapy lack comparable fertility evidence. Pituitary tumors, allergy and poorly monitored hormone stimulation are key concerns.

• In studies, timed pulses from a pump helped women whose periods stopped from low brain signals to ovulate. (Studied in a trial)
• In men with diagnosed hormone deficiency, pump treatment can restore sperm production, studies show. (Studied in a trial)
• A pump form (Lutrepulse) was once approved to help women with this hormone deficiency ovulate; it is now discontinued. (Drug label)
• People report adding shots during testosterone therapy to limit testicle shrinkage; fertility benefit is unproven. (Reported by users)

Uses in the sources

• Pituitary LH-response testing is described in authorized UK and French product information. (Clinician-published) (source)
• Pulsatile pumps have been studied for ovulation and sperm production in GnRH deficiency. (Studied in a trial) (source)
• People add intermittent shots to TRT to limit testicular shrinkage; fertility benefit remains unproven. (Reported by users) (source)
• A seven-man Down syndrome pilot explored cognition; this does not establish general nootropic use. (Studied in a trial) (source)

Gonadorelin dosage

Typical reported dose: 200 mcg every 3.5 days (twice a week)

• Pituitary response test: SC: 100 mcg once single diagnostic injection, under the skin. Clinician-published. Studied in: Adults undergoing an organized pituitary test. (source)
• Pituitary response test: IV: 100 mcg once single diagnostic injection, into a vein. Clinician-published. Studied in: Adults undergoing an organized pituitary test. (source)
• LutrePulse: 10 mcg pulses: 10 mcg per pulse every 90 minutes every 90 minutes by pump, under the skin. Studied in a trial. Studied in: Women with primary amenorrhea and hypogonadotropic hypogonadism. (source)
• LutrePulse: 15 mcg pulses: 15 mcg per pulse every 90 minutes every 90 minutes by pump, under the skin. Studied in a trial. Studied in: Women with primary amenorrhea and hypogonadotropic hypogonadism. (source)
• LutrePulse: 20 mcg pulses: 20 mcg per pulse every 90 minutes every 90 minutes by pump, under the skin. Studied in a trial. Studied in: Women with primary amenorrhea and hypogonadotropic hypogonadism. (source)
• Male CHH: response-guided pump: Start 10 mcg per pulse every 90 minutes every 90 minutes by pump, under the skin. Clinician-published. Studied in: Men with confirmed congenital hypogonadotropic hypogonadism. (source)

These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.

Work out syringe units with the dosing calculator

How to mix Gonadorelin

Comes as: UK diagnostic 100 mcg powder vial.

Mixed with: 1.0 mL sterile water for injections for the UK 100 mcg vial..

Common vial sizes: 0.1 mg. Common water amounts: 1 mL.

• Authorized UK product instructions, not an FDA/EMA label protocol.
• These instructions do not establish stability of community 2 mg multi-dose vials.

Before mixing: UK diagnostic product: store below 25°C.

After mixing: Refrigerate after mixing and use within 24 hours; discard unused solution.

Gonadorelin side effects and risks

Reported side effects

• Pump-site skin allergy: 7/20 (35%) in one male pump cohort; not a bolus test rate., moderate (source)
• Pain, swelling or itching: UK bolus label: 0.1% to <1%., mild (source)
• Headache, dizziness or nausea: UK bolus label: 0.01% to <0.1%., mild (source)
• Allergy or airway spasm: UK label classifies hypersensitivity and bronchospasm as rare., serious (source)
• IV-line infection or vein inflammation: Historical IV line complications averaged 7%; includes more than infection., serious (source)
• Multiple pregnancy or ovarian over-response: 12% multiple pregnancy in the 1990 program; 1.6% twins in the 2022 cohort., serious (source)
• Pituitary bleeding in a tumor: unknown, serious. Sudden severe headache or vision loss needs emergency assessment. (source)

Stop and get help if

• Sudden severe headache, vision change, vomiting or collapse: Seek emergency care for possible pituitary bleeding.
• Throat swelling, wheeze or faintness after injection: Seek emergency care for possible severe allergy.
• Fever, spreading redness or chills with a pump or IV line: Get urgent assessment for possible infection.
• Severe pelvic pain, rapid weight gain or breathlessness: Get urgent assessment for ovarian over-response.

Who should avoid it

• pregnant: UK product information says not to administer during pregnancy.
• breastfeeding: UK product information says not to administer while nursing.
• tryingToConceive: Specialist fertility use requires diagnosis and monitoring.
• under18: Pediatric research is not an adult self-use regimen.
• hormoneSensitiveCancer: Precaution: gonadorelin raises sex hormones; breast or prostate cancer requires an oncology plan.
• other: GnRH can trigger bleeding into a pituitary adenoma.
• other: Prior allergy to gonadorelin or its excipients can recur.
• other: Primary gonadal failure or poor pituitary reserve can limit response; diagnose the cause first.
• testedAthlete: Prohibited at all times in male athletes under WADA S2.2.1.
• other: Stop for signs of severe allergy or a serious pump-site infection.

Interactions

• Testosterone and other sex hormones: These can alter LH/FSH response. Intermittent gonadorelin has not been shown to preserve fertility during TRT.
• Glucocorticoids: Can affect pituitary gonadotropin secretion and diagnostic interpretation.
• Prolactin-raising drugs: Dopamine antagonists can blunt the GnRH response through higher prolactin.
• Spironolactone, methyldopa and digoxin: Can alter measured gonadotropins and test interpretation.
• Other GnRH medicines: Other drugs acting on the same axis can suppress or change response; they are not dose substitutes.
• Clomiphene with ovulation induction: A historical hyperstimulation case also used clomiphene; combination monitoring matters.

Product quality risks

• An FDA recall included compounded gonadorelin because of sterility concerns.
• A June 2026 FDA warning identified an unapproved gonadorelin product. A research label does not establish approval.
• No representative assay survey of online gonadorelin vials was found.

What to expect

At least 51 studies in separate reviews, 35 in women and 16 in men. More reports are listed; twice-weekly shots alongside testosterone therapy lack a controlled fertility trial.

Key studies

• Hypothalamic amenorrhea: 35 studies: Pulsatile GnRH can induce ovulation in hypothalamic amenorrhea. (source)
• Male fertility: 16 GnRH studies: Pulsatile GnRH can restore sperm production in diagnosed hormone deficiency. (source)
• GnRH versus gonadotropins: Earlier sperm appearance did not establish a higher pregnancy rate. (source)
• Lutrepulse: multicenter fertility study: The historical program studied pump therapy, not occasional TRT injections. (source)
• LutrePulse: posted phase 3 results: Posted randomized results show an ovulation signal with higher pump doses. (source)
• FHA: 25-year pump cohort: Pump therapy produced high ovulation rates with few multiple pregnancies. (source)

Gonadorelin FAQ

• Is Gonadorelin FDA-approved? Yes: Factrel, human product; discontinued (historical diagnostic gonadorelin hydrochloride product.); Lutrepulse Kit; discontinued (historical gonadorelin acetate for GnRH-deficient ovulation induction.). All human products under these NDAs are discontinued. No approved TRT-add-on indication; veterinary Factrel is a different product.
• How do people take it? Under the skin, every 3.5 days. Source: reported by users, not an established dose.
• What's the difference between Gonadorelin and Kisspeptin-10? Gonadorelin: a short-acting fertility hormone used in tests and specialist pump therapy. Kisspeptin-10: a short-acting experimental peptide that triggers reproductive hormone release. Why people pair them: reported as a second reproductive-axis stimulant. No human combination trial was found.
• Can I take it with Kisspeptin-10? Reported as a second reproductive-axis stimulant. No human combination trial was found. Hormone and fertility effects of the combination are unknown. Source: reported by users. Ask a doctor before combining anything.
• Is it banned in sport? Yes. It is banned in and out of competition (WADA 2026). The S2.2.1 restriction applies to male athletes. The ingredient, formulation and athlete-specific therapeutic use exemption must be checked with the antidoping authority.
• How long does a mixed vial last? Refrigerate after mixing and use within 24 hours; discard unused solution.